On November 13, 2026 Incyte Corporation (the "Company") reported it has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the Company’s selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer, which had been expected to begin in the fourth quarter of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s determination was based on the prioritization of its clinical development portfolio and was not based on any safety or efficacy findings from the INCB123667 clinical program. The Company does not expect this determination to affect its financial guidance or its previously disclosed long-term outlook.

(Press release, Incyte, NOV 13, 2026, View Source [SID1234674749])